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Abstract
Purpose TAS-102 is a combination of the thymidine-based
nucleoside analog trifluridine and the thymidine phospho-
rylase inhibitor tipiracil. Efficacy and safety of TAS-102 in
patients with metastatic colorectal cancer (mCRC) refrac-
tory or intolerant to standard therapies were evaluated in
the phase 3 RECOURSE trial. Results of RECOURSE
demonstrated significant improvement in overall survival
(OS) and progression-free survival (PFS) with TAS-102
versus placebo [hazard ratio (HR) = 0.68 and 0.48 for OS
and PFS, respectively; both P\ 0.001]. The current anal-
ysis evaluates efficacy and safety of TAS-102 in the
RECOURSE Spanish subgroup.
Methods Primary and key secondary endpoints were
evaluated in a post hoc analysis of the RECOURSE
Spanish subgroup, using univariate and multivariate anal-
yses. Safety and tolerability were reported with descriptive
statistics.
Results The RECOURSE Spanish subgroup included 112
patients (mean age 61 years, 62 % male). Median OS was
6.8 months in the TAS-102 group (n = 80) versus
4.6 months in the placebo group (n = 32) [HR = 0.47;
95 % confidence interval (CI): 0.28–0.78; P = 0.0032).
Median PFS was 2.0 months in the TAS-102 group and
1.7 months in the placebo group (HR = 0.47; 95 % CI:
0.30–0.74; P = 0.001). Eighty (100 %) TAS-102 versus 31
(96.9 %) placebo patients had adverse events (AEs). The
most common drug-related CGrade 3 AE was neutropenia
(40 % TAS-102 versus 0 % placebo). There was 1 (1.3 %)
case of febrile neutropenia in the TAS-102 group versus
none in the placebo group.
Conclusions In the RECOURSE Spanish subgroup, TAS-
102 was associated with significantly improved OS and
PFS versus placebo, consistent with the overall
RECOURSE population. No new safety signals were
identified.
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Introduction
TAS-102 is an oral combination treatment consisting of
trifluridine (FTD), a thymidine-based nucleoside analog,
and tipiracil hydrochloride (TPI), at a molar ratio of 1:0.5
(weight ratio: 1:0.471). It is approved for use in Japan and
the United States, and also has been recently approved in
Europe. The primary cytotoxic mechanism of oral FTD is
through incorporation into DNA following phosphorylation
by thymidine kinase, leading to DNA dysfunction (Fig. 1)
[1, 2]. This mechanism is distinct from that of 5-fluo-
rouracil (5-FU) and other fluoropyrimidines that produce
their cytotoxic effects through inhibition of thymidylate
synthase. Although phosphorylated FTD does inhibit this
enzyme, this activity is secondary to its direct effects on
DNA when administered orally. This may explain the
activity of TAS-102 in human cancer xenografts resistant
to 5-FU [1, 3]. TPI improves the bioavailability of FTD by
inhibiting its catabolism by thymidine phosphorylase [4].
The combination of these two agents makes TAS-102 an
attractive candidate for treatment of patients with
metastatic colorectal cancer (mCRC) who are refractory to
fluoropyrimidines [5].
TAS-102 has shown promise in a number of phase 1 and
2 trials [6–10]. A phase 2, double-blind, randomized,
controlled trial conducted in Japanese patients with mCRC
refractory to 5-FU, irinotecan, and oxaliplatin demon-
strated a median overall survival (OS) of 9.0 months with
TAS-102 compared with 6.6 months in the placebo group
[hazard ratio (HR) = 0.56; 95 % confidence interval (CI),
0.39–0.81; P = 0.001]. More recently, in the phase 3
RECOURSE trial in patients with mCRC refractory to
standard therapies, TAS-102 demonstrated a significant
improvement compared with placebo in median OS (7.1 vs
5.3 months; HR = 0.68; 95 % CI, 0.58–0.81; P\ 0.001)
and progression-free survival (PFS) (2.0 vs 1.7 months;
HR = 0.48; 95 % CI, 0.41–0.57; P\ 0.001) [11].
The initial phase 2 trial of TAS-102 included only
patients from Japan, and a subset of patients enrolled in
RECOURSE were from Europe [9, 11]. It is of interest,
therefore, to assess the efficacy of TAS-102 in patients
enrolled in Spain, which accounted for a sizeable portion
(14 %) of patients enrolled in the international
RECOURSE trial. The objective of the current analysis
was to evaluate the efficacy and safety of TAS-102 in the
Spanish subgroup of patients enrolled in the RECOURSE
trial.
Fig. 1 Comparison of the mechanisms of action of TAS-102 and
5-FU. 5-FU fluorouracil; dTMP and dTTP deoxythymidine mono- and
triphosphate; dUMP deoxyuridine monophosphate; F3dTMP, F3-
dTDP, and F3dTTP trifluorodeoxythymidine mono-, di-, and
triphosphate; FdUMP fluorodeoxyuridine monophosphate; TK1
thymidine kinase 1; TPase thymidine phosphorylase; TPI tipiracil
hydrochloride; TS thymidylate synthase




The protocol for the RECOURSE study has been described
in detail previously [11]. Briefly, the RECOURSE trial was
a global, multicenter, randomized, double-blind, placebo-
controlled phase 3 trial comparing TAS-102 plus best
supportive care with placebo plus best supportive care.
Patients were randomly assigned in a 2:1 ratio to receive
TAS-102 or placebo and were stratified according to KRAS
status (wild type, mutant status), time since diagnosis of
first metastasis (\18 months, C18 months), and geo-
graphic region [Japan or Western (United States, Europe,
and Australia combined)]. This analysis focuses on those
patients in the European stratum who were randomized in
Spain. Subjects were randomized at 11 different centers in
Spain. This trial is registered with ClinicalTrials.gov
number, NCT01607957.
The study was conducted according to the principles of
the Declaration of Helsinki and the International Council
for Harmonisation Good Clinical Practice Guidelines, and
the study was approved by institutional review boards at
each participating center. All patients provided written
informed consent.
Patients
Eligible patients with metastatic, biopsy-documented ade-
nocarcinoma of the colon or rectum who had received C2
prior lines of therapy with standard chemotherapies and
had been refractory to antitumor therapy were eligible for
randomization. Prior therapy could have included adjuvant
treatment if tumor recurrence had occurred within
6 months, tumor progression within 3 months after the last
administration of therapy, or if clinical adverse events
precluded rechallenge with standard chemotherapy.
Knowledge of KRAS status was required, and patients must
have received prior chemotherapy with a fluoropyrimidine,
oxaliplatin, irinotecan, and bevacizumab, and cetuximab or
panitumumab if they had KRAS wild-type tumors. In
addition, patients had to be C18 years of age, have ade-
quate bone-marrow, liver, and renal function, and have an
Eastern Cooperative Oncology Group (ECOG) perfor-
mance status of 0 or 1. Patients were centrally randomized
via an Interactive Voice/Web Response System based on a
dynamic allocation method.
Endpoints
The primary endpoint was OS, which was defined as the
time from randomization to death from any cause.
Secondary endpoints included PFS, which was defined as
the time from randomization to the first radiographic con-
firmation of disease progression or death from any cause,
overall response rate (the proportion of patients with a
complete or partial response), disease control rate (the
proportion of patients with a complete or partial response,
or stable disease, with stable disease assessed at least
6 weeks after starting treatment), time to deterioration of
ECOG performance status to 2 or greater, and safety.
Radiographic assessments were conducted every 8 weeks,
and treatment was continued until disease progression as
defined by RECIST (version 1.1) [12], clinical progression,
development of serious adverse events, study withdrawal,
death, or a decision by the physician that discontinuation
was in the patient’s best interest. Adverse events were
classified and graded according to the National Cancer
Institute Common Terminology Criteria for Adverse
Events, version 4.03.
Statistical analysis
The study protocol included a prespecified analysis of
outcomes and safety according to geographic subregion.
The same methodology was used for this post hoc analysis
of the Spanish subgroup. OS and PFS were analyzed in the
intent-to-treat population with the use of a two-sided,
stratified log-rank test, with the HR and two-sided 95 %
confidence intervals based on a stratified Cox proportional
hazards model and the associated Kaplan–Meier survival
estimates. The median follow-up time for survival was
calculated by means of the reverse Kaplan–Meier method.
Objective response and disease control rates were com-
pared using the Fisher’s exact test in the subgroup of
patients in the intent-to-treat population who had measur-
able disease at baseline. The time to deterioration of ECOG
performance status to 2 (defined as: ambulatory and cap-
able of all self-care but unable to carry out any work
activities; up and about more than 50 % of waking hours)
was analyzed with a similar approach to that employed for
analysis of OS. Adverse events and laboratory abnormali-
ties were summarized for all patients who received at least
one dose of study drug. The number of hospitalizations,
number and percentage of patients hospitalized, reason for
hospitalization, and the total duration of hospitalization
were summarized descriptively by treatment group.
Results
Patients
Of the 112 patients randomized to the RECOURSE study
in Spain, 80 were in the TAS-102 arm and 32 in the
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placebo arm. The Spanish subgroup, therefore, represents
14 % of the overall RECOURSE population and 28 % of
the prespecified European stratum. Patient and tumor
characteristics for subjects enrolled and randomized in
Spain are shown in Table 1, along with characteristics for
the overall population. Because patients enrolled in Spain
represented a significant portion of the overall and pre-
specified European stratum, baseline characteristics were
well balanced between the two arms. However, there were
some differences between the Spanish and overall popu-
lations: the Spanish subgroup was entirely Caucasian vs
57.6 % of the overall population; Spanish patients had
worse ECOG performance status with 68.8 % having a
performance status of 1 vs 44.0 % in the overall population
(31.3 and 56.0 % had performance status of 0 in the two
populations, respectively); and more patients in the Spanish
subgroup had had prior regorafenib treatment (25.9 vs
18.0 %).
Efficacy
The median OS in the Spanish subgroup was 6.8 months in
the TAS-102 group, significantly greater than the
4.6 months observed in the placebo group (HR = 0.47;
95 % CI, 0.28–0.78; P = 0.0032) (Fig. 2a; Table 2). The
1-year OS rate was 27.5 % (95 % CI, 14.0–42.9) in the
TAS-102 arm and 20.4 % (95 % CI, 7.9–36.9) in the pla-
cebo arm (Fig. 2b). Similarly, median PFS in the TAS-102
group from in Spanish patients was 2.0 months, signifi-
cantly longer than 1.7 months observed in the placebo
group (HR = 0.47; 95 % CI, 0.30–0.74; P\ 0.001)
(Fig. 3; Table 2). As shown in Figs. 2, 3, and Table 2,
these results were consistent with the OS and PFS reported
for the overall population.
There was no significant difference between arms in
terms of the best overall response rate and the disease
control rate in the Spanish subgroup. No patients in either
group had a complete response. The TAS-102 arm had a
partial response rate of 3.9 % (3 patients) vs 0 % in the
placebo arm. The disease control rate was 39.5 and 19.4 %
in the TAS-102 and placebo arms, respectively. The
median time to deterioration of ECOG performance status
to 2 was 5.4 months for the TAS-102 group versus
3.3 months for the placebo group (HR = 0.31; 95 % CI,
0.18–0.54; P\ 0.0001). These results were consistent with
response and disease control rates in the overall population.
Safety and tolerability
Overall Grade C3 adverse events in the Spanish subgroup,
regardless of causation, occurred in 72.5 % of patients in
the TAS-102 arm and 56.3 % in the placebo arm. The most
common nonhematologic adverse events of any grade seen
with TAS-102 in C30 % of the Spanish subgroup were
asthenia, nausea, decreased appetite, and diarrhea
(Table 3). Asthenia and back pain were the most common
(C5 %) nonhematologic Grade C3 adverse events seen
with TAS-102. The incidence of asthenia and mucosal
inflammation was somewhat higher among Spanish
patients than in the overall population and the incidence of
fatigue was somewhat lower, but there were no other
notable differences in the incidence of individual adverse
events.
There were similar incidences of laboratory abnormali-
ties in the Spanish population compared with the overall
population. For Grade C3 laboratory abnormalities,
myelosuppression was common with TAS-102, with 40
and 16.3 % experiencing neutropenia or leukopenia, com-
pared with no patients in the placebo arm; in addition,
13.8 % experienced anemia, compared with 6.3 % in the
placebo arm. Lymphocytopenia and thrombocytopenia
were also higher in the TAS-102 arm compared with the
placebo arm. Total bilirubin and alkaline phosphatase were
elevated in a substantial portion of the Spanish population
in both treatment groups (Table 3).
Importantly, the rate of serious adverse events and
hospitalizations was lower in the TAS-102 arm than in the
placebo arm: 20 and 37.5 % of patients experienced serious
adverse events in the TAS-102 and placebo arms, respec-
tively. A similar proportion of patients were hospitalized
during the study, with the vast majority being due to
serious adverse events; one patient in the TAS-102 arm
was hospitalized due to febrile neutropenia and one patient
in the placebo arm was hospitalized due to health deteri-
oration (Table 3). Overall, TAS-102 was considered to be
well tolerated in the Spanish population.
Discussion
The results observed in the Spanish subgroup (14 % of the
total study population) were consistent with the results of
the overall RECOURSE study. Indeed, TAS-102 was
associated with significant improvements in OS and PFS in
the Spanish population. In Spanish patients, the risk of
death and risk of disease progression or death were both
reduced by 53 % with TAS-102 compared with placebo
(P = 0.0032 and P = 0.001, respectively). The reduction
in the risk of death with TAS-102 in this population was
greater than that observed in the overall population, with an
HR of 0.47 (95 % CI: 0.28–0.78) in the Spanish group and
0.68 (0.58–0.81) in the overall population [11]. The HR of
OS in the Spanish subgroup was lower than that of the
overall RECOURSE population. This may be explained by
the fact that the Spanish population had a substantially
higher percentage of patients with an ECOG status of 1
230 Clin Transl Oncol (2017) 19:227–235
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Table 1 Patient demographics and baseline characteristics [11]
Spanish subgroup Overall population
TAS-102 (n = 80) Placebo (n = 32) TAS-102 (n = 534) Placebo (n = 266)
Gender, male, n (%) 48 (60.0) 21 (65.6) 326 (61.0) 165 (62.0)
Age, years, median (range) 61.5 (27–81) 62.5 (39–78) 63.0 (27–82) 63.0 (27–82)
Race, n (%)
Caucasian 80 (100) 32 (100) 306 (57.3) 155 (58.3)
Asian/Oriental 0 0 184 (34.5) 94 (35.3)
Other/not collected 0 0 44 (8.2) 17 (6.4)
ECOG PS, n (%)
0 24 (30.0) 11 (34.4) 301 (56.4) 147 (55.3)
1 56 (70.0) 21 (65.6) 233 (43.6) 119 (44.7)
KRAS status,a n (%)
Wild type 35 (43.8) 17 (53.1) 262 (49.1) 131 (49.2)
Mutant 45 (56.3) 15 (46.9) 272 (50.9) 135 (50.8)
Time since diagnosis of first metastasis,a n (%)
\18 months 16 (20.0) 7 (21.9) 111 (20.8) 55 (20.7)
C18 months 64 (80.0) 25 (78.1) 423 (79.2) 211 (79.3)
Time from initial diagnosis, months, mean (SD) 42.4 (24.7) 46.6 (34.7) 44.1 (29.3) 45.5 (28.3)
Primary tumor site, n (%)
Colon 49 (61.3) 23 (71.9) 338 (63.3) 161 (60.5)
Rectal 31 (38.8) 9 (28.1) 196 (36.7) 105 (39.5)
Number of organ sites involved, n (%)b
1–2 51 (64) 19 (59) 309 (58) 146 (55)
C3 29 (36) 13 (41) 225 (42) 120 (45)
Number of prior regimens,c n (%)
1 0 0 0 0
2 15 (18.8) 7 (21.9) 95 (17.8) 45 (16.9)
3 16 (20.0) 7 (21.9) 119 (22.3) 54 (20.3)
C4 49 (61.3) 18 (56.3) 320 (59.9) 167 (62.8)
All prior systemic cancer therapeutic agents,c,d n (%)
Bevacizumab 80 (100.0) 31 (96.9) 534 (100) 265 (99.6)
Cetuximab/panitumumab 41 (51.3) 19 (59.4) 278 (52.1) 144 (54.1)
Fluoropyrimidinee 80 (100.0) 32 (100.0) 534 (100) 266 (100)
Irinotecan 80 (100.0) 32 (100.0) 534 (100) 266 (100)
Oxaliplatin 80 (100.0) 32(100.0) 534 (100) 266 (100)
Regorafenib 20 (25.0) 9 (28.1) 91 (17) 53 (19.9)
Other 73 (91.3) 30 (93.8) 471 (88.2) 237 (89.1)
Refractory to fluoropyrimidines,f n (%) 72 (90.0) 31 (96.9) 497 (93.1) 240 (90.2)
ECOG PS, Eastern Cooperative Oncology Group performance status; SD, standard deviation
a As randomized
b Based on the number of unique lesion sites (organs) per patient
c Includes all prior systemic therapies (neoadjuvant, adjuvant, metastatic)
d Patients with multiple levels are counted in each applicable category
e Fluoropyrimidine includes 5-FU-containing agents fluorouracil, capecitabine, doxifluridine, S-1, tegafur, and UFT
f Refractory the last time fluoropyrimidine was part of the regimen. Refractory defined as: regimens with radiologic progression B93 days from
the last dose of the last component of the regimen for regimens intended to treat metastatic disease (or of missing intent), and with radiologic
progression B186 days for adjuvant/neoadjuvant regimens
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and, therefore, a worse prognosis. The Kaplan–Meier
curves are largely coincident for the TAS-102 arms in
Spanish patients and overall (Fig. 2). There was no sig-
nificant benefit in favor of TAS-102 in terms of best overall
response and disease control rates, although both showed
trends favoring TAS-102. Similar results were seen for the
Phase 3 trial of regorafenib which noted similar OS and
PFS for Japanase and primarily Caucasian non-Japanese
patients [13]. A recent analysis of European cancer reg-
istries showed that the mean 5-year OS for colorectal and
Spanish Populaon Overall Populaon
Month TAS-102, % (95% CI) Placebo, % (95% CI) TAS-102, % (95% CI) Placebo, % (95% CI)
3 88.8 (79.5-94.0) 65.6 (46.6-79.3) 86.0 (82.7-88.6) 75.1 (69.4-79.9)
6 53.2 (41.3-63.7) 28.5 (13.7-45.3) 57.8 (53.5-61.9) 43.5 (37.4-49.4)
9 36.6 (23.4-49.9) 20.4 (7.9-36.9) 40.1 (35.6-44.6) 24.2 (18.9-29.9)
12 27.5 (14.0-42.9) 20.4 (7.9-36.9) 26.6 (22.2-31.1) 17.6 (12.7-23.1)
A
B  
Fig. 2 a Kaplan–Meier curves for overall survival in the Spanish subgroup and overall RECOURSE populations; b overall survival estimates for
the TAS-102 and placebo treatment groups at months 3, 6, 9, and 12
Table 2 Overall survival and
progression-free survival for the
Spanish subgroup and overall
RECOURSE population (ITT
population) [11]
Spanish subgroup Overall population
TAS-102 (n = 80) Placebo (n = 32) TAS-102 (n = 534) Placebo (n = 266)
Median OS, months 6.8 4.6 7.1 5.3
HR (95 % CI) 0.47 (0.28–0.78) 0.68 (0.58–0.81)
P value P = 0.0032 P\ 0.001
Median PFS, months 2.0 1.7 2.0 1.7
HR (95 % CI) 0.47 (0.30–0.74) 0.48 (0.41–0.57)
P value P = 0.001 P\ 0.0001
CI confidence interval, HR hazard ratio, ITT intention to treat, OS overall survival, PFS progression-free
survival
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rectal cancers in Spanish patients was similar to the
European mean for those cancers, with mean OS in
Southern Europe being similar to that of Northern and
Central Europe, and greater than that in the UK, Ireland,
and Eastern Europe [14]. This suggests that survival for
mCRC in Spanish patients is representative of Europe as a
whole and that the results presented here corroborate
results for the whole continent [15].
There were a number of differences in the baseline
characteristics of the Spanish population when compared
with the overall RECOURSE population, as might be
expected in a multicenter international study that included
patients from Europe, Asia, the United States, and Aus-
tralia. All of the patients from Spain were Caucasian,
compared with 57.6 % of the overall population (34.8 % of
the patients in the trial were Asian). The demonstrated
efficacy of TAS-102 in Caucasian Spanish patients is
encouraging for the generalizability of the results of the
RECOURSE study to different populations. This is sig-
nificant because the phase 2 trial of TAS-102 in mCRC was
conducted solely in Japanese patients [9], and differences
in response have been noted previously between Western
and Japanese subjects for gefitinib in lung cancer [16]. In
the prespecified analysis of regional subgroups in
RECOURSE, the OS difference between TAS-102 and
placebo groups in the Japanese population (HR: 0.75, 95 %
CI: 0.57–1.00) was not as pronounced as in the US (HR:
0.56, 95 % CI: 0.34–0.94) or European (HR: 0.62, 95 %
CI: 0.48–0.80) populations, which were largely composed
of Caucasian patients. Demographics as well as the small
size of the Spanish subgroup relative to the overall study
may explain the apparent survival benefit in the Spanish
population.
There was some imbalance of colon cancer versus rectal
cancer in the placebo group enrolled in Spain, compared
with the TAS-102 arm and the overall population.
Although patients in the Spanish subgroup had similar time
from diagnosis, number of rounds of prior chemotherapy,
and KRAS mutation prevalence as the overall RECOURSE
population, the Spanish subpopulation had 50 % higher
incidence of ECOG performance status of 1 than the
overall study population, which indicates poorer health
status. This higher incidence of a worse ECOG perfor-
mance status would be expected to have a negative impact
on outcomes since performance status on its own has been
shown to be a good prognostic factor for patients with
advanced cancer [17]. Despite this, the time to deteriora-
tion to performance status C2 in Spanish patients was
similar to that observed in the overall population for both
TAS-102 (5.4 months versus 5.7 months) and placebo (3.3
vs 4.0 months) [11]. The reasons for this discrepancy in the
ECOG performance status of Spanish patients and the
overall population are unclear. However, they are consis-
tent with a similar analysis of the Phase 3 CORRECT trial
Fig. 3 Kaplan–Meier curves for radiologic progression-free survival in the Spanish subgroup and overall RECOURSE populations
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of regorafenib which noted a higher rate of ECOG per-
formance status of 0 among Japanese patients compared to
the primarily Caucasian non-Japanese population [13]. It is
possible, therefore, that regional or cultural differences in
interpretation of ECOG performance status definitions had
a role.
TAS-102 was generally well tolerated in this subgroup
of patients from the RECOURSE study, with the overall
safety profile being similar to that of the overall popula-
tion. Importantly, no new safety signals were seen in this
Spanish population. As with the overall study, neutrope-
nia was the most frequently observed, clinically mean-
ingful laboratory abnormality or adverse event, with one
patient being hospitalized for febrile neutropenia. The
only substantial difference reported in the safety profile of
TAS-102 between the Spanish and overall RECOURSE
populations was a higher incidence of asthenia and lower
incidence of fatigue in Spanish patients. This difference is
likely due to subtle local differences in interpretation of
the definition of these two overlapping adverse events
[18]. The rate of serious adverse events and hospitaliza-
tions in the Spanish subgroup was somewhat lower than
in the overall population, but this could merely reflect
local differences in healthcare expenditure, socioeconomic
status, lifestyle, and general health status of the popula-
tion [14], as well as the relatively low number of patients
in this cohort. The lack of difference in adverse events
differs from that seen in the recent trial of regorafenib,
which noted a higher incidence of certain adverse events
among Japanese patients than non-Japanese patients—in-
cluding a higher incidence of Grade 3 adverse events
[13].
Table 3 Adverse events in the Spanish subgroup and overall RECOURSE population (as-treated population) [11]
Spanish population Overall population
TAS-102 (n = 80)a Placebo (n = 32)a TAS-102 (n = 533)a Placebo (n = 265)a
Any AE, n (%) 80 (100) 31 (97) 524 (98) 247 (93)
Grade C3 AEs, n (%) 58 (73) 18 (56) 370 (69) 137 (52)
Most common AEs, any grade (C20 % in TAS-102 group), n (%)
Nausea 31 (39) 5 (16) 258 (48) 63 (24)
Vomiting 20 (25) 3 (9) 148 (28) 38 (14)
Decreased appetite 29 (36) 10 (31) 208 (39) 78 (29)
Fatigue 11 (14) 3 (9) 188 (35) 62 (23)
Diarrhea 24 (30) 5 (16) 170 (32) 33 (13)
Abdominal pain 13 (16) 3 (9) 79 (15) 36 (14)
Asthenia 49 (61) 13 (41) 97 (18) 30 (11)
Mucosal inflammation 18 (23) 8 (25) 30 (5.6) 12 (4.5)
Most common grade C3 AEs (C5 % in TAS-102 group), n (%)
Asthenia 10 (13) 2 (6) 18 (3) 8 (3)
Back pain 4 (5) 1 (3) 9 (2) 2 (1)
Grade C3 laboratory abnormalities that worsened by baseline C1 grade,a n (%)
Neutropenia 32 (40) 0 200/528 (38) 0
Leukopenia 13 (16) 0 113/528 (21) 0
Lymphocytopenia 8/76 (11) 2/31 (7) 112/522 (21) 26/262 (10)
Anemia 11 (14) 2 (6) 96/528 (18)b 8/263 (3)
Increased total bilirubin 7 (8) 6 (19) 45/526 (9) 31/262 (12)
Increased alkaline phosphatase 5 (6) 6/31 (19) 42/526 (8) 28/262 (11)
Thrombocytopenia 2 (3) 0 27/528 (5) 1/263 (\1)
Serious AEs 16 (20) 12 (38) 158 (30) 89 (34)
Hospitalizations, n (%) 16 (20) 12 (38) 165 (31) 96 (36)
Due to serious AE 14/16 (88) 12/12 (100) 140/165 (85) 85/96 (89)
Due to febrile neutropenia 1/16 (6) 0 14/165 (9) 0
Due to health deterioration 0 1/12 (8) 15/165 (9) 9/96 (9)
a The total as-treated population serves as denominator unless otherwise indicated
b One patient was diagnosed with Grade 4 anemia
AE adverse event
234 Clin Transl Oncol (2017) 19:227–235
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The data presented here are limited by the fact that this
was an unplanned post hoc analysis of the subgroup of
patients who were randomized in Spain. As such, this
analysis may not have had sufficient statistical power to
draw definitive conclusions about the efficacy of TAS-102.
However, this population represents a substantial propor-
tion of the European geographic region, an analysis of
which was preplanned. Furthermore, the Spanish popula-
tion was larger than the American and Australian geo-
graphic subregions for which there were preplanned
analyses.
The results of this analysis of a subgroup of Spanish
patients with mCRC refractory to standard therapies who
were enrolled in the international, multicenter, randomized,
placebo-controlled RECOURSE study indicate that the
results of the larger trial are generally applicable in this
subpopulation. TAS-102 was found to impart significant
improvements in OS and PFS compared with placebo,
similar to that seen in the overall trial. TAS-102 was
generally well tolerated in this population of Spanish
patients, with no new safety signals unique to this partic-
ular population identified. TAS-102 may be a good treat-
ment option for Spanish patients with mCRC who are
refractory to standard treatments.
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